Table 1.
Patient characteristics
| Characteristics | Total | Sunitinib | Sorafenib | P-value |
|---|---|---|---|---|
| Age, years; median (range) | 53.5 (33–75) | 47 (33–66) | 54 (34–68) | 0.72 |
| Sex, n (%) | 0.49 | |||
| Male | 16 (88.9) | 7 (77.8) | 6 (100.0) | |
| Female | 2 (11.1) | 2 (22.2) | 0 | |
| BMI, kg/m2; median (range) | 24.07 (18.09–30.42) | 23.94 (18.09–29.76) | 25.83 (22.41–30.42) | 0.20 |
| Tumor laterality, n (%) | 1.00 | |||
| Left | 4 (22.2) | 2 (22.2) | 1 (16.7) | |
| Right | 14 (77.8) | 7 (77.8) | 5 (83.3) | |
| ECOG performance status, n (%) | 0.32 | |||
| 0 | 2 (11.1) | 2 (22.2) | 0 | |
| 1 | 14 (77.8) | 6 (66.7) | 5 (83.3) | |
| 2 | 2 (11.1) | 1 (11.1) | 1 (16.7) | |
| TMT, n (%) | NA | |||
| Sorafenib | 6 (33.3) | 9 (100.0) | ||
| Sunitinib | 9 (50.0) | 6 (100.0) | ||
| Axitinib | 3 (16.7) | |||
| Cycles of TMT, weeks; median (range) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.48 |
| Clinical stage, n (%) | NA | |||
| T3b | 17 (94.4) | 9 (100.0) | 6 (100.0) | |
| T3c | 1 (5.6) | 0 | 0 | |
| Nodal stage, n (%) | 0.58 | |||
| N0 | 12 (66.7) | 5 (55.6) | 5 (83.3) | |
| N1 | 6 (33.3) | 4 (44.4) | 1 (16.7) | |
| Metastatic disease, n (%) | 2 (11.1) | 0 | 1 (16.7) | 0.43 |
| Thrombus level, n (%) | 0.67 | |||
| I | 1 (5.6) | 0 | 1 (16.7) | |
| II | 12 (66.7) | 8 (88.9) | 4 (66.6) | |
| III | 4 (22.2) | 1 (11.1) | 1 (16.7) | |
| IV | 1 (5.6) | 0 | 0 | |
| Histology, n (%) | 0.66 | |||
| ccRCC | 15 (83.3) | 8 (88.9) | 5 (83.3) | |
| Papillary cell RCC | 2 (11.1) | 1 (11.1) | 0 | |
| Chromophobe RCC | 1 (5.6) | 0 | 1 (16.7) | |
| Fuhrman grade, n (%) | 0.11 | |||
| 2 | 3 (20.0) | 1 (12.5) | 2 (40.0) | |
| 3 | 9 (60.0) | 4 (50.0) | 3 (60.0) | |
| 4 | 3 (20.0) | 3 (37.5) | 0 | |
| ASA score, n (%) | 0.23 | |||
| 1+2 | 14 (77.8) | 6 (66.7) | 6 (100.0) | |
| 3+4 | 4 (22.2) | 3 (33.3) | 0 |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; ccRCC, clear cell renal cell carcinoma; ECOG, Eastern Cooperative Oncology Group; RCC, renal cell carcinoma; TMT, targeted molecular therapy.